Abstract
The potential for co-prescription of the anti-human immunodeficiency virus (anti-HIV) drug efavirenz (EFV) and the oral anticoagulant warfarin (WAR) is currently high as EFV is a drug of choice for HIV type 1 infection and because cardiovascular disease is increasing among HIV-infected individuals. However, clinical reports of EFV-WAR interaction, leading to WAR overdosing, call for elucidation of the mechanisms involved in this drug-drug interaction. Here we present the first report demonstrating competition of the two drugs for the same binding site of human serum albumin. Using ligand-based nuclear magnetic resonance experiments, this study proves that EFV has an effect on the concentration of free WAR. This previously unidentified EFV-WAR interaction represents a potential risk factor that should be taken into account when considering treatment options. (c) 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 443-446 |
Number of pages | 4 |
Journal | International Journal Of Antimicrobial Agents |
Volume | 42 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2013 |